A Rutgers professor’s novel research into targeting and silencing defective, disease-causing RNA molecules has led to the launch of Ceptur Therapeutics, a startup that has raised $75 million in Series A funding. The initial research that led to the creation of Ceptur was conducted by principal investigator Samuel I. Gunderson, PhD, associate professor of molecular biology and biochemistry at Rutgers-New Brunswick’s School of Arts and Sciences. Gunderson’s research focused on Ribonucleic acid (RNA), specifically how to manipulate and control RNA to understand its functions and treat different genetic diseases, such as certain blood cancers and neurological disorders. To read the full story.